Cover Story: A SNAPSHOT OF 2003 Rx MARKET

Orforglipron lowered A1C and body weight more than oral semaglutide 25 mg at 52 weeks, but the estimate comes from an indirect comparison.

Brian Smith, PharmD, explains how direct-to-consumer GLP-1 pathways broaden initial access but endanger long-term patient adherence.

Pharmacists face burnout and financial strain as PBMs take big cuts, prompting urgent calls for reform to protect patient care and community pharmacies.

What pharmacy technicians say would actually make them feel seen on World Pharmacy Technician Day, and the other 364 days of the year.

The analysis is not a head-to-head trial, and the weight loss gap reached statistical significance under 1 of 2 estimands.

A 1.6-million-birth analysis finds that adoption of a 2016 trial's antibiotic protocol climbed sharply in US hospitals, with a drop in infection rates.

New findings suggest semaglutide's benefits may extend well beyond diabetes and weight loss and into airway disease and mood disorders.

First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.